Last-Resort cancer drug made available to patients who have no other options
NCT ID NCT07215832
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 24 times
Summary
This program provides early access to the investigational drug selinexor for people with multiple myeloma, lymphoma, sarcoma, or other cancers who have exhausted all approved treatments and cannot join a clinical trial. Patients must get approval from their doctor and local health authorities. The goal is to offer a potential treatment option when no others remain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.